Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 2Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Hodgkin Disease 7Lymphoma 3Vulvar Neoplasms 1Neoplasms, Second Primary 1Neoplasms, Germ Cell and Embryonal 1Neoplasms 1

Interventions

Etoposide 3etoposide phosphate 2Paclitaxel 2Ifosfamide 2Cisplatin 2tremelimumab 1pembrolizumab 1durvalumab 1cabozantinib 1Sirolimus 1Quality of Life 1Proton Therapy 1Mesna 1Granulocyte Colony-Stimulating Factor 1Cyclophosphamide 1Celecoxib 1Carboplatin 1Bleomycin 1Automobiles 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Neoplasms, Germ Cell and Embryonal × Bleomycin × Clear all
NCT01873326 2025-07-03

Paclitaxel, Ifosfamide and Cisplatin (TIP) Versus Bleomycin, Etoposide and Cisplatin (BEP) for Patients With Previously Untreated Intermediate- and Poor-risk Germ Cell Tumors

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
92 enrolled

Neoplasms, Germ Cell and Embryonal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡